Dermatologic toxicities of targeted anticancer therapies.

摘要: The discovery of the intricate intracellular signaling networks that regulate normal cellular proliferation and survival but can also drive oncogenic process when aberrantly activated has led to emergence targeted agents in oncology. introduction such resulted improved more tolerable treatments, reducing systemic toxicities as myelosuppression. Nevertheless, it become evident these are associated with a wide spectrum dermatologic often manifest cosmetically sensitive areas may affect majority patients. Associated pain pruritus negatively impact quality life, resulting dose modification or treatment interruptions interfere potentially life-prolonging therapy. Extensive efforts throughout past decade have concentrated on describing clinicohistopathologic characteristics, elucidating underlying mechanisms, investigating potential management strategies. Currently, however, proposed guidelines arise from expert opinions, anecdotal evidence, few data clinical trials. This article reviews variety used alone combination other modalities, delineating their presentation, options.